NPPB and interstitial lung disease: Recently, however, inhaled treprostinil administered four times daily for 16 weeks improved exercise tolerance and N-terminal pro-brain natriuretic peptide (NT pro-BNP) levels in ILD associated PH (37), leading to its FDA approval as the first drug for ILD associated WHO group 3 PH.